Nektar Therapeutics

Nektar Therapeutics is a research-based biopharmaceutical company. The company's proprietary drugs and drug candidates that have either received regulatory approval or are being developed by the company or in collaboration with other pharmaceutical companies or independent investigators include: ONZEALD?, a topoisomerase I inhibitor targeted for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule for moderate to severe chronic pain; NKTR-214, a CD122-biased immune-stimulatory cytokine targeted for oncology; NKTR-358 for autoimmune disease; NKTR-262 targeted for solid tumors; and NKTR-255 targeted for immuno-oncology.
  • TickerNKTR
  • ISINUS6402681083
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

Sel Hardy

Nektar Therapeutics

ValuEngine Rating and Forecast Report for NKTR

ValuEngine Rating and Forecast Report for NKTR

Sel Hardy

Nektar Therapeutics

ValuEngine Rating and Forecast Report for NKTR

ValuEngine Rating and Forecast Report for NKTR

Sel Hardy

Nektar Therapeutics

Sel Hardy

Nektar Therapeutics

Sel Hardy

Nektar Therapeutics

Sel Hardy

Nektar Therapeutics

Sel Hardy

Nektar Therapeutics

Sel Hardy

Nektar Therapeutics

Sel Hardy

Nektar Therapeutics

ValuEngine Rating and Forecast Report for NKTR

ValuEngine Rating and Forecast Report for NKTR

ValuEngine Rating and Forecast Report for NKTR

ValuEngine Rating and Forecast Report for NKTR

ValuEngine Rating and Forecast Report for NKTR

ValuEngine Rating and Forecast Report for NKTR

ValuEngine Rating and Forecast Report for NKTR

ValuEngine Rating and Forecast Report for NKTR

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • A number of Consumer Cyclical names continue to reflect leadership. (ex. SBUX, RRGB, MCD, PZZA, and ROST.) • The Financial Sector has a number of attractive names developing major bases and staging RS reversals. (ex. SIVB, STT, AXP, SPGI, CME, GS, and JEF) • The Technology Sector has a number of technically attractive constituents. (ex. AMD, OLED, MPWR, CRUS, BR, FIS, VRSN, SAIC, LDOS, AAOI, BELFB, FARO, STX, and AAPL) .

Dave Nicoski ...
  • John Betz

Vermilion Compass: Weekly Equity Strategy

• Bullish but selective. As we alluded to last week, our long-term bullish outlook remains intact. However, looking through the charts we find a growing list of extended and parabolic patterns. While we continue to remain bullish, we acknowledge the likelihood of backing and filling, or a pause, is building. The further a stock's price action moves from its 200-day, the greater the possibility of a corrective reversion to the mean, or pullback. In last week's Compass our example was Boeing Corporation (BA). The stock is trading 40% above its 200-day moving average, and this rate of momentum i...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch